Is GLP-1 (7-37) FDA approved?

GLP-1 (7-37) is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

Is Retatrutide FDA approved?

Retatrutide is investigational and not FDA approved. It is discussed for research and educational purposes only, not as medical guidance.

How is GLP-1 (7-37) administered in research settings?

In research settings, GLP-1 (7-37) is typically administered via the subcutaneous or intravenous routes. PeptideBase does not provide dosing or administration instructions.

How is Retatrutide administered in research settings?

In research settings, Retatrutide is typically administered via the subcutaneous route. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›GLP-1 (7-37) vs Retatrutide

Peptide Comparison

GLP-1 (7-37) vs Retatrutide

Name: GLP-1 (7-37) vs Retatrutide — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are Metabolic peptides.

GLP-1 (7-37)

GLP-1 fragment

Fat LossNot EvaluatedResearch Only

33 providers listed

Full GLP-1 (7-37) profile →

Retatrutide

LY3437943

Fat LossInvestigationalResearch Only

Half-life: ~6 days

94 providers listed

Full Retatrutide profile →

Bottom line

Retatrutide carries stronger published evidence (RCT, 13 key studies) than GLP-1 (7-37) (RCT, 2); both are research compounds.

Quick Verdict

GLP-1 (7-37)

Evidence

Emerging Clinical

Half-life

—

Retatrutide

Evidence

Clinical

Half-life

~6 days

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	Retatrutide
Further along in FDA review	Retatrutide
More provider options (33 vs 94)	Retatrutide

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

GLP-1 (7-37)

Retatrutide

Mechanism Family

Metabolic

Half-life

—

~6 days

FDA Status

not evaluated

investigational

Admin Routes

subcutaneous, intravenous

subcutaneous

Availability

Research Only

Providers

33 listed

94 listed

Avail. Notes

—

Triple GIP/GLP-1/glucagon agonist by Eli Lilly. Pivotal Phase 3 readouts across obesity (TRIUMPH-1, May 2026), obesity + knee osteoarthritis (TRIUMPH-4, Dec 2025), and type 2 diabetes (TRANSCEND-T2D-1, Mar 2026); OSA trial in program. Not FDA-approved; regulatory submission expected 2026–2027. NCT05929066.

Research Evidence

GLP-1 (7-37)

Emerging ClinicalRCT · 2 key studies · most recent 2026

Retatrutide

ClinicalRCT · 13 key studies · most recent 2026

Research Citations

GLP-1 (7-37)

Cohort2026 · Protein Sci

Aggregation-driven expression of liraglutide precursors using engineered mini-tags in Escherichia coli.

RCT1999 · Diabetes Care

GLP-1 treatment of obese patients with type 2 diabetes mellitus: improvement of insulin responsiveness by red…

Retatrutide

RCT2023 · New England Journal of Medicine

Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial

Review2026 · Eur J Clin Pharmacol

Dysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature review.

Review2026 · Lancet Diabetes Endocrinol

Beyond weight loss: multisystem benefits of obesity medications.

Cohort2026 · BMJ

Retatrutide: Triple acting jab for type 2 diabetes lowers blood sugar and boosts weight loss, trial reports.

+9 more

About GLP-1 (7-37)

Binds GLP-1 receptors in the pancreas, gut, and brain. Stimulates glucose-dependent insulin secretion and suppresses glucagon. Central GLP-1 receptor activation reduces food intake via hypothalamic pathways.

Research Areas

appetite suppressioninsulin sensitivityblood glucose regulation

About Retatrutide

Triple GIP/GLP-1/glucagon receptor agonist; targets three pathways for synergistic fat reduction

Research Areas

profound weight lossappetite suppressionmetabolic improvement

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

GLP-1 (7-37)

Absolute Contraindications

Personal or family history of medullary thyroid carcinoma (MTC)Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)Known hypersensitivity to the drug or excipients

Warnings & Cautions

Acute pancreatitisPregnancy (discontinue; not for use in pregnancy)Gallbladder disease / cholelithiasisDiabetic retinopathy complications (reported with GLP-1 receptor agonist use)Severe GI disease / gastroparesis / ileus riskHypoglycemia when combined with insulin or sulfonylureasAcute kidney injury secondary to volume depletion

Class-based (investigational)

Retatrutide

Absolute Contraindications

Personal or family history of medullary thyroid carcinoma (MTC)Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)Known hypersensitivity to the drug or excipients

Warnings & Cautions

Class-based (investigational)

Price (per mg)

GLP-1 (7-37)

Not enough vendor pricing yet.

Retatrutide

$10.90/mg

$8.34 – $12.73 range

7 vendors

View price index →Find providers →

Find Providers

Where to source these peptides

Providers offering

GLP-1 (7-37)

33 listed

Browse directory →

Providers offering

Retatrutide

94 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Metabolic Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated July 27, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). GLP-1 (7-37) vs Retatrutide — Per-mg Price Comparison. Retrieved July 29, 2026, from https://peptidebase.io/peptides/compare/glp-1-7-37/retatrutide

https://peptidebase.io/peptides/compare/glp-1-7-37/retatrutide Methodology License Download JSON Download CSV